CA2222133C - Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen - Google Patents
Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen Download PDFInfo
- Publication number
- CA2222133C CA2222133C CA002222133A CA2222133A CA2222133C CA 2222133 C CA2222133 C CA 2222133C CA 002222133 A CA002222133 A CA 002222133A CA 2222133 A CA2222133 A CA 2222133A CA 2222133 C CA2222133 C CA 2222133C
- Authority
- CA
- Canada
- Prior art keywords
- patch
- day
- estrogen
- deacetyl norgestimate
- woman
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Abstract
Compositions and methods for preventing ovulation in a woman are provided, a s well as compositions and methods for female hormone replacement therapy. The compositions can be administered by the use of a transdermal patch. The patc h will administer 17-deacetyl norgestimate alone or in combination with an estrogen such as ethinyl estradiol to women.
Description
S
1 N 1)r, MA1. NA1(.H AND METHOD FORADMINISTFR
17-DEACETYL NOR rF~TIMATF AT lINF QR jN
COMBINATION WITH A E TRO N
Descn ion This invention relates to transdermal drug delivery. More particularly, it concerns patches and methods for transdermally administering 17-deacetyl norgestimate either 1 S alone or in combination with an estrogen, particularly ethinyl estradiol.
Background Combinations of norgestimate (Ngm) and ethinyl estradiol (EE) are administered orally to women as a contraceptive. Bringer J., Am. J. 0b tet. necol. (1992) 1øø:1969-77. McGuire, J.C. et al., A_m__. J. Obstet. ynecol. (1990) x:2127-suggests that orally administered Ngm metabolizes to 17-deacetyl norgestimate (17-d-Ngm), 3-ketonorgestimate, and levonorgestrel (Lng) and that these metabolites may contribute to the pharmacologic response to the orally administered drug.
Chien et al., U.S. Pat. No. 4,906,169 describes transdermal patches for co delivering estrogens and progestins to women for contraception. EE is mentioned as one 2S of the estrogens that may be administered from the patch and Ngm and Lng are mentioned as possible progestins that may be administered.
Applicants are unaware of any art describing the administration of 17-d-Ngm alone or in combination with any estrogen by transdermal or other routes of administration.
disclosure of the Invention This invention provides compositions and a method for preventing ovulation or for providing hormone replacement therapy by the administration of an effective amount of 17-deacteyl norgestimate to a woman. In one aspect, the 17-deacteyl norgestimate is co-administered with an ovulation inhibiting amount of estrogen to the woman.
The compositions are preferably administered transdermally.
Accordingly, one aspect of this invention is a transdermal patch for preventing ovulation in a woman comprising: a backing layer; and a matrix layer underlying the backing layer, the matrix layer comprising a mixture of 17-d-Ngm and a pressure sensitive adhesive and being adapted to be in diffusional communication with the skin of the woman and to administer an ovulation-inhibiting amount of 17-d-Ngm to said skin.
Another aspect of the invention is a transdermal patch for administering 17-d-Ngm and estrogen to a woman, the patch comprising: a backing layer; and a matrix layer underlying the backing layer, the matrix layer comprising a mixture of 17-d-Ngm, an estrogen, and a pressure sensitive adhesive, and being adapted to be in diffusional communication with the skin of the woman and to co-administer an ovulation-inhibiting amount of said 17-d-Ngm and estrogen to the woman through the skin. These patches are also can be used to provide hormone replacement therapy.
1 N 1)r, MA1. NA1(.H AND METHOD FORADMINISTFR
17-DEACETYL NOR rF~TIMATF AT lINF QR jN
COMBINATION WITH A E TRO N
Descn ion This invention relates to transdermal drug delivery. More particularly, it concerns patches and methods for transdermally administering 17-deacetyl norgestimate either 1 S alone or in combination with an estrogen, particularly ethinyl estradiol.
Background Combinations of norgestimate (Ngm) and ethinyl estradiol (EE) are administered orally to women as a contraceptive. Bringer J., Am. J. 0b tet. necol. (1992) 1øø:1969-77. McGuire, J.C. et al., A_m__. J. Obstet. ynecol. (1990) x:2127-suggests that orally administered Ngm metabolizes to 17-deacetyl norgestimate (17-d-Ngm), 3-ketonorgestimate, and levonorgestrel (Lng) and that these metabolites may contribute to the pharmacologic response to the orally administered drug.
Chien et al., U.S. Pat. No. 4,906,169 describes transdermal patches for co delivering estrogens and progestins to women for contraception. EE is mentioned as one 2S of the estrogens that may be administered from the patch and Ngm and Lng are mentioned as possible progestins that may be administered.
Applicants are unaware of any art describing the administration of 17-d-Ngm alone or in combination with any estrogen by transdermal or other routes of administration.
disclosure of the Invention This invention provides compositions and a method for preventing ovulation or for providing hormone replacement therapy by the administration of an effective amount of 17-deacteyl norgestimate to a woman. In one aspect, the 17-deacteyl norgestimate is co-administered with an ovulation inhibiting amount of estrogen to the woman.
The compositions are preferably administered transdermally.
Accordingly, one aspect of this invention is a transdermal patch for preventing ovulation in a woman comprising: a backing layer; and a matrix layer underlying the backing layer, the matrix layer comprising a mixture of 17-d-Ngm and a pressure sensitive adhesive and being adapted to be in diffusional communication with the skin of the woman and to administer an ovulation-inhibiting amount of 17-d-Ngm to said skin.
Another aspect of the invention is a transdermal patch for administering 17-d-Ngm and estrogen to a woman, the patch comprising: a backing layer; and a matrix layer underlying the backing layer, the matrix layer comprising a mixture of 17-d-Ngm, an estrogen, and a pressure sensitive adhesive, and being adapted to be in diffusional communication with the skin of the woman and to co-administer an ovulation-inhibiting amount of said 17-d-Ngm and estrogen to the woman through the skin. These patches are also can be used to provide hormone replacement therapy.
Modes For Carrying Out The 1 vention This invention provides compositions and methods for preventing ovulation in a woman comprising administering and an ovulation inhibiting amount of 17-deacteyl norgestimate. An effective amount can be from about 150 to about 350 pg/day and preferably from about 175 to about 300 ~,g/day of 17-deacteyl norgestimate. In one aspect, , the 17-deacteyl norgestimate is co-administered with an ovulation inhibiting amount of an estrogen such as ethinyl estradiol. An effective amount is from about 150 to about 350 ~g/day and preferably from about 175 to 300 ~g/day of 17 deacteyl norgestimate and from 10 to 35 ~g/day of ethinyl estradiol.
The transdermal patches of the invention provide contraception for women. They also are adapted for hormone replacement therapy.
The patches are intended to deliver 17-d-Ngm and, optionally an estrogen, to the skin continuously for an extended time period, typically 1-7 days and preferably for 7 days.
When the patches are worn for contraception, a patch will typically be placed on the skin on the fifth day of the menstrual cycle, and replaced as needed until 21 days of wearing have elapsed. For instance, in the case of a 7-day patch, three patches will be required to deliver the drugs) for the 21-day period. If desired a placebo patch may be worn thereafter until the fifth day of the succeeding menstrual cycle. This regimen is repeated for each menstrual cycle.
17-d-Ngm and estrogens both inhibit ovulation, albeit by separate pathways. 17-d-Ngm inhibits the release of luteinizing hormone (LH), whereas the predominant effect of estrogen is to inhibit the secretion of follicle-stimulating hormone (FSH).
Thus, when a combination of 17-d-Ngm and estrogen is administered according to the invention, ovulation is prevented by inhibiting the ovulatory stimulus and/or by inhibiting the growth of follicles. 17-d-Ngm administration is believed to be advantageous relative to the parent compound (Ngm) or its other metabolites in that 17-d-Ngm inhibits little or no androgenic activity.
The effective dose of 17-d-Ngm for inhibiting ovulation is normally in the range of about 150 to about 350 pg/day, preferably from about 175 to about 300 pg/day, and more preferably from about 175 to about 250 pg/day. The patches of the invention will typically have a basal surface area (i.e. the area in diffusional contact with the skin) between 10 and 50 cm2. The effective dose of estrogen for inhibiting ovulation will depend upon the particular estrogen being co-administered. For instance, when the estrogen is ethinyl estradiol, the dose will normally be at least 10 pg/day, preferably from about 10 to 35 pg/day, and most preferably approximately 20 p,g/day. The patches will contain sufficient amounts of 17-d-Ngm and, when present, estrogen, to provide such daily doses for the intended patch wear time. Typically, such doses are from about 20 p.g/day to about 200 p,g/day, and preferably from about 30 pg/day to 150 p,g/day of ethinyl estradiol.
1 S The patches of this invention are matrix or monolithic-type laminated structures.
Such transdermal patches are well known in the art. They comprise a matrix layer of the drugs) admixed with a pressure sensitive adhesive and a backing layer. The matrix serves as both the drug reservoir and the means by which the patch is affixed to the skin.
Prior to use, the patch will also include an impermeable release liner layer.
The backing layer is impermeable to the drug and other components of the matrix and defines the top face surface of the patch. It may be made of a single layer or film of polymer, or be a laminate of one or more polymer layers and metal foil.
Examples of polymers suitable for use in making backing films are polyvinylchloride, polyvinylidene chloride, polyolefms such as ethylene-vinyl acetate copolymers, polyethylene, and polypropylene, polyurethane, and polyesters such as polyethylene terephthalate.
The pressure-sensitive adhesive of the matrix will normally be a solution polyacrylate, a silicone, or polyisobutylene (PIB). Such adhesives are well known in the transdermal art. See, for instance, the Handbook of Pressure Sensitive Adhesive Technology, 2nd Edition (1989) Van Nostrand, Reinhold.
Pressure sensitive solution polyacrylate adhesives are made by copolymerizing one or more acrylate monomers ("acrylate" is intended to include both acrylates and methacrylates), one or more modifying monomers, and one or more functional group-containing monomers in an organic solvent. The acrylate monomers used to make these polymers are normally alkyl acrylates of 4-17 carbon atoms, with 2-ethylhexyl acrylate, butyl acrylate, and :isooctyl acrylate being preferred. Modifying monomers are typically included to alter the Tg of the polymer. Such monomers as vinyl acetate, ethyl acrylate and methacrylate, and methyl methacrylate are useful for this purpose. The functional group-containing monomer provides sites for crosslinking. The functional 1'. 0 groups of these monomers are preferably carboxyl, hydroxy or combinations thereof.
Examples of monomers that provide such groups are acrylic acid, methacrylic acid and hydroxy-containing monomers such as hydroxyethyl acrylate. The polyacrylate adhesives are preferably crosslinked using a crosslinking agent to improve their physical properties, (e.g., creep and shear resistance). The crosslinking density should be low since high degrees of crosslinking may affect the adhesive properties of the copolymer adversely. Examples of crosslinking agents are disclosed in U.S. Pat. No.
5,393,529.
Solution polyacrylate pressure sensitive adhesives are commercially available under tradenames such as GELVA'~" and DURO-TAKT"" from 3M.
Polyisobutylene adhesives are mixtures of high molecular weight (HMW) PIB
and low molecular weight (L:MVI~ PIB. Such mixtures are described in the art, e.g., W09116085. The molecular weight of the HMW PIB will usually be in the range of about 700,000 to 2,000,000 Da, whereas that of the LMW PIB will typically range between 35,000 to 60,000. The molecular weights referred to herein are weight average molecular weight. The weight ratio of HMW PIB to LMW PIB in the adhesive will normally range between 1:1 to 1:10. The PIB adhesive will also normally include a tackifier such as polybutene oil and high Tg, low molecular weight aliphatic resins such as the ESCOREZT"'' resins available from Exxon Chemical. Polyisobutylene polymers are available commercially under the tradename VISTANEXT"" from Exxon Chemical.
The silicone adhesives that may be used in forming the matrix are typically high molecular weight polydimethyl siloxanes or polydimethyldiphenyl siloxanes.
Formulations of silicone adhesives that are useful in transdermal patches are described in U.S. Patent. Nos. 5,232,702, 4,906,169 and 4,951,622.
S Estrogens that may be combined with 17-d-Ngm in the matrix include 17-J-estradiol and esters thereof such as estradiol valerate, estradiol cypionate, estradiol acetate, estradiol benzoate, and EE. EE is a preferred estrogen for use in combination with 17-d-Ngm. EE/17-d-Ngm combinations may favorably effect metabolic parameters such as elevation of serum high density lipoprotein and reduction of the low density lipoprotein/high density lipoprotein ratio in serum.
In addition to the pressure sensitive adhesive, 17-d-Ngm, and optional estrogen, the matrix will typically contain su~cient amounts of permeation enhancers to increase the permeability of the 17-d-Ngm and estrogen through the skin and provide fluxes in the ranges described above. Examples of skin permeation enhancers that may be included in the matrix are described in U.S. Patent Nos. 5,059,426, 4,973,468, 4,906,463 and 4,906,169, and include, but are not limited to lactate ester of C~2 to CIg aliphatic alcohol, lauryl lactate, oleic acid or PGML. The amount of permeation enhancer included in the matrix will depend upon the particular enhancer(s) used. In most instances then enhancer will constitute in the range of 1 to 20% by weight of the matrix.
The matrix may contain other additives depending upon the particular adhesive used. For instance, materials, such as polyvinyl pyrrolidone (PVP), that inhibit drug crystallization, hygroscopic agents that improve the duration of wear, or additives that improve the physical (e.g., cold flow) or adhesive (e.g., tack, cohesive strength) properties of the matrix may be included.
The patches described above also are useful for providing hormone replacement therapy. When used to provide hormone replacement therapy, the matrix is constructed so as to provide an effective amount of 17-d-Ngm and estrogen for the intended purpose.
Typically, the matrix and therefore the patch is constructed to provide from about 150 to about 350 pg/day, and preferably from about 175 to about 300 pg/day 17-d-Ngm co-administered with from about 5 to about 45 pg/day and preferably from about 10 to about 35 p,g/day of an ethinyl estradiol. In an alternative embodiment, the patch will administer from about 200 to about 350 pg/day, and preferably from about 175 to about 300 ~.g/day 17-d-Ngm co-administered with from about 20 to about 175 pg/day and preferably from about 30 to about 150 ~g/day of 17-~i-estradiol. The patch is applied for 7 days and replaced with a new patch (for 7 days) for the duration of the therapy.
The patches of the invention may be fabricated using procedures known in the transdermal patch art. The procedure will generally involve formulating the matrix (i.e., mixing the adhesive, drug(s), permeation enhancer, and additives, if any), casting the matrix onto the backing or release liner layer, removing solvent from the matrix and applying the backing/release liner layer as the case may be. As is apparent to those of skill in the art, the matrix composition having an effective amount of the drug dispersed therein can be incorporated into various transdermal constructions and therefore, applicants are not limited to the embodiments exemplified below.
The following examples further illustrate the invention. These examples are not intended to limit the invention in any manner. Unless indicated otherwise, stated percentages are by weight.
EXAMPLES
x 1 Duro-Tak 87-2287 is a solution polyacrylate adhesive available from National Starch and Chemical Co. Its monomer composition is: vinyl acetate, 2-ethylhexyl acrylate, hydroxyethyl acrylate, and glycidyl methacrylate. It contains no crosslinking agent. It is available as a 50% solids solution in ethyl acetate. w Mixtures of Duro-Tak 87-2287, 0.26% aluminum acetylacetonate crosslinker, 6%
17-d-Ngm, 1 % EE, and various permeation enhancers were prepared. These mixtures were cured and cast as a 100 micron thick (wet) layer onto a 3M 1022 polyester backing and dried. Skin flux tests were carried out on the resulting assemblies according to the procedure described in col. 7 of U.S. 5,252,334. HPLC was used to assay for 17-d-Ngm and EE. A Perkin Elmer HPLC system with Diedoarray detector set at 245 nm and run for 17-d-Ngm and EE, respectively. The mobile phase was 55% water, 45%
acetonitl~ile at a flow rate of 1.0 ml/min. Retention time was 4.5 and 3.0 min. for 17-d-Ngm and EE, respectively. Details of the formulations and the results of the flux tests are shown in Table 1 below.
Table 1 Flux lLtg/cm~l~
Formulation _17 d_Ngm 2% TG + 4% OL 0.30f0.04 0.06110.007 2% TG + 10% ML 0.39f0.03 0.07610.005 2% TG + 10% PGML 0.29f0.06 0.05710.009 3% TG 0.2410.06 0.043f0.011 4% TG + 15% ML 0.3810.001 0.0720.002 TG = thioglycerol OL = oleic acid ML = methyl laurate PGML = propylene glycol monolaurate x 1 Silicone 4202 is a polydimethylsiloxane adhesive from Dow Corning. It was mixed with 17-d-Ngm, EE, 7% PVP (K30 from BASF; dissolved in n-propanol) and various enhancers. These mixtures were cast as a 100 micron thick (wet) layer onto a 3M
1022 polyester backing and dried. Skin flux tests were carried out on the resulting assemblies as in Example 1. The details of the formulations and the results of the flux studies are reported in Table 2 below.
The transdermal patches of the invention provide contraception for women. They also are adapted for hormone replacement therapy.
The patches are intended to deliver 17-d-Ngm and, optionally an estrogen, to the skin continuously for an extended time period, typically 1-7 days and preferably for 7 days.
When the patches are worn for contraception, a patch will typically be placed on the skin on the fifth day of the menstrual cycle, and replaced as needed until 21 days of wearing have elapsed. For instance, in the case of a 7-day patch, three patches will be required to deliver the drugs) for the 21-day period. If desired a placebo patch may be worn thereafter until the fifth day of the succeeding menstrual cycle. This regimen is repeated for each menstrual cycle.
17-d-Ngm and estrogens both inhibit ovulation, albeit by separate pathways. 17-d-Ngm inhibits the release of luteinizing hormone (LH), whereas the predominant effect of estrogen is to inhibit the secretion of follicle-stimulating hormone (FSH).
Thus, when a combination of 17-d-Ngm and estrogen is administered according to the invention, ovulation is prevented by inhibiting the ovulatory stimulus and/or by inhibiting the growth of follicles. 17-d-Ngm administration is believed to be advantageous relative to the parent compound (Ngm) or its other metabolites in that 17-d-Ngm inhibits little or no androgenic activity.
The effective dose of 17-d-Ngm for inhibiting ovulation is normally in the range of about 150 to about 350 pg/day, preferably from about 175 to about 300 pg/day, and more preferably from about 175 to about 250 pg/day. The patches of the invention will typically have a basal surface area (i.e. the area in diffusional contact with the skin) between 10 and 50 cm2. The effective dose of estrogen for inhibiting ovulation will depend upon the particular estrogen being co-administered. For instance, when the estrogen is ethinyl estradiol, the dose will normally be at least 10 pg/day, preferably from about 10 to 35 pg/day, and most preferably approximately 20 p,g/day. The patches will contain sufficient amounts of 17-d-Ngm and, when present, estrogen, to provide such daily doses for the intended patch wear time. Typically, such doses are from about 20 p.g/day to about 200 p,g/day, and preferably from about 30 pg/day to 150 p,g/day of ethinyl estradiol.
1 S The patches of this invention are matrix or monolithic-type laminated structures.
Such transdermal patches are well known in the art. They comprise a matrix layer of the drugs) admixed with a pressure sensitive adhesive and a backing layer. The matrix serves as both the drug reservoir and the means by which the patch is affixed to the skin.
Prior to use, the patch will also include an impermeable release liner layer.
The backing layer is impermeable to the drug and other components of the matrix and defines the top face surface of the patch. It may be made of a single layer or film of polymer, or be a laminate of one or more polymer layers and metal foil.
Examples of polymers suitable for use in making backing films are polyvinylchloride, polyvinylidene chloride, polyolefms such as ethylene-vinyl acetate copolymers, polyethylene, and polypropylene, polyurethane, and polyesters such as polyethylene terephthalate.
The pressure-sensitive adhesive of the matrix will normally be a solution polyacrylate, a silicone, or polyisobutylene (PIB). Such adhesives are well known in the transdermal art. See, for instance, the Handbook of Pressure Sensitive Adhesive Technology, 2nd Edition (1989) Van Nostrand, Reinhold.
Pressure sensitive solution polyacrylate adhesives are made by copolymerizing one or more acrylate monomers ("acrylate" is intended to include both acrylates and methacrylates), one or more modifying monomers, and one or more functional group-containing monomers in an organic solvent. The acrylate monomers used to make these polymers are normally alkyl acrylates of 4-17 carbon atoms, with 2-ethylhexyl acrylate, butyl acrylate, and :isooctyl acrylate being preferred. Modifying monomers are typically included to alter the Tg of the polymer. Such monomers as vinyl acetate, ethyl acrylate and methacrylate, and methyl methacrylate are useful for this purpose. The functional group-containing monomer provides sites for crosslinking. The functional 1'. 0 groups of these monomers are preferably carboxyl, hydroxy or combinations thereof.
Examples of monomers that provide such groups are acrylic acid, methacrylic acid and hydroxy-containing monomers such as hydroxyethyl acrylate. The polyacrylate adhesives are preferably crosslinked using a crosslinking agent to improve their physical properties, (e.g., creep and shear resistance). The crosslinking density should be low since high degrees of crosslinking may affect the adhesive properties of the copolymer adversely. Examples of crosslinking agents are disclosed in U.S. Pat. No.
5,393,529.
Solution polyacrylate pressure sensitive adhesives are commercially available under tradenames such as GELVA'~" and DURO-TAKT"" from 3M.
Polyisobutylene adhesives are mixtures of high molecular weight (HMW) PIB
and low molecular weight (L:MVI~ PIB. Such mixtures are described in the art, e.g., W09116085. The molecular weight of the HMW PIB will usually be in the range of about 700,000 to 2,000,000 Da, whereas that of the LMW PIB will typically range between 35,000 to 60,000. The molecular weights referred to herein are weight average molecular weight. The weight ratio of HMW PIB to LMW PIB in the adhesive will normally range between 1:1 to 1:10. The PIB adhesive will also normally include a tackifier such as polybutene oil and high Tg, low molecular weight aliphatic resins such as the ESCOREZT"'' resins available from Exxon Chemical. Polyisobutylene polymers are available commercially under the tradename VISTANEXT"" from Exxon Chemical.
The silicone adhesives that may be used in forming the matrix are typically high molecular weight polydimethyl siloxanes or polydimethyldiphenyl siloxanes.
Formulations of silicone adhesives that are useful in transdermal patches are described in U.S. Patent. Nos. 5,232,702, 4,906,169 and 4,951,622.
S Estrogens that may be combined with 17-d-Ngm in the matrix include 17-J-estradiol and esters thereof such as estradiol valerate, estradiol cypionate, estradiol acetate, estradiol benzoate, and EE. EE is a preferred estrogen for use in combination with 17-d-Ngm. EE/17-d-Ngm combinations may favorably effect metabolic parameters such as elevation of serum high density lipoprotein and reduction of the low density lipoprotein/high density lipoprotein ratio in serum.
In addition to the pressure sensitive adhesive, 17-d-Ngm, and optional estrogen, the matrix will typically contain su~cient amounts of permeation enhancers to increase the permeability of the 17-d-Ngm and estrogen through the skin and provide fluxes in the ranges described above. Examples of skin permeation enhancers that may be included in the matrix are described in U.S. Patent Nos. 5,059,426, 4,973,468, 4,906,463 and 4,906,169, and include, but are not limited to lactate ester of C~2 to CIg aliphatic alcohol, lauryl lactate, oleic acid or PGML. The amount of permeation enhancer included in the matrix will depend upon the particular enhancer(s) used. In most instances then enhancer will constitute in the range of 1 to 20% by weight of the matrix.
The matrix may contain other additives depending upon the particular adhesive used. For instance, materials, such as polyvinyl pyrrolidone (PVP), that inhibit drug crystallization, hygroscopic agents that improve the duration of wear, or additives that improve the physical (e.g., cold flow) or adhesive (e.g., tack, cohesive strength) properties of the matrix may be included.
The patches described above also are useful for providing hormone replacement therapy. When used to provide hormone replacement therapy, the matrix is constructed so as to provide an effective amount of 17-d-Ngm and estrogen for the intended purpose.
Typically, the matrix and therefore the patch is constructed to provide from about 150 to about 350 pg/day, and preferably from about 175 to about 300 pg/day 17-d-Ngm co-administered with from about 5 to about 45 pg/day and preferably from about 10 to about 35 p,g/day of an ethinyl estradiol. In an alternative embodiment, the patch will administer from about 200 to about 350 pg/day, and preferably from about 175 to about 300 ~.g/day 17-d-Ngm co-administered with from about 20 to about 175 pg/day and preferably from about 30 to about 150 ~g/day of 17-~i-estradiol. The patch is applied for 7 days and replaced with a new patch (for 7 days) for the duration of the therapy.
The patches of the invention may be fabricated using procedures known in the transdermal patch art. The procedure will generally involve formulating the matrix (i.e., mixing the adhesive, drug(s), permeation enhancer, and additives, if any), casting the matrix onto the backing or release liner layer, removing solvent from the matrix and applying the backing/release liner layer as the case may be. As is apparent to those of skill in the art, the matrix composition having an effective amount of the drug dispersed therein can be incorporated into various transdermal constructions and therefore, applicants are not limited to the embodiments exemplified below.
The following examples further illustrate the invention. These examples are not intended to limit the invention in any manner. Unless indicated otherwise, stated percentages are by weight.
EXAMPLES
x 1 Duro-Tak 87-2287 is a solution polyacrylate adhesive available from National Starch and Chemical Co. Its monomer composition is: vinyl acetate, 2-ethylhexyl acrylate, hydroxyethyl acrylate, and glycidyl methacrylate. It contains no crosslinking agent. It is available as a 50% solids solution in ethyl acetate. w Mixtures of Duro-Tak 87-2287, 0.26% aluminum acetylacetonate crosslinker, 6%
17-d-Ngm, 1 % EE, and various permeation enhancers were prepared. These mixtures were cured and cast as a 100 micron thick (wet) layer onto a 3M 1022 polyester backing and dried. Skin flux tests were carried out on the resulting assemblies according to the procedure described in col. 7 of U.S. 5,252,334. HPLC was used to assay for 17-d-Ngm and EE. A Perkin Elmer HPLC system with Diedoarray detector set at 245 nm and run for 17-d-Ngm and EE, respectively. The mobile phase was 55% water, 45%
acetonitl~ile at a flow rate of 1.0 ml/min. Retention time was 4.5 and 3.0 min. for 17-d-Ngm and EE, respectively. Details of the formulations and the results of the flux tests are shown in Table 1 below.
Table 1 Flux lLtg/cm~l~
Formulation _17 d_Ngm 2% TG + 4% OL 0.30f0.04 0.06110.007 2% TG + 10% ML 0.39f0.03 0.07610.005 2% TG + 10% PGML 0.29f0.06 0.05710.009 3% TG 0.2410.06 0.043f0.011 4% TG + 15% ML 0.3810.001 0.0720.002 TG = thioglycerol OL = oleic acid ML = methyl laurate PGML = propylene glycol monolaurate x 1 Silicone 4202 is a polydimethylsiloxane adhesive from Dow Corning. It was mixed with 17-d-Ngm, EE, 7% PVP (K30 from BASF; dissolved in n-propanol) and various enhancers. These mixtures were cast as a 100 micron thick (wet) layer onto a 3M
1022 polyester backing and dried. Skin flux tests were carried out on the resulting assemblies as in Example 1. The details of the formulations and the results of the flux studies are reported in Table 2 below.
Formulation Flux ,~gJ ~~(~
17-d-Nam % Enhancer 17_d-Ngm 4 0.5 5% ML + 1% TG 0.65f0.09 0.069+0.007 6 0.5 5% ML + 1 % TG 0.600.04 0.0430.004 6 0.5 14% PGML 0.48f0.04 0.070f0.01 6 0.5 14% (TC:PGML; 0.580.05 0.062f0.01 80:20) 4 0.5 4% TG + 5% ML 0.6410.01 0.07810.01 4 0.5 2% ML 0.5110.08 0.07410.008 2 0.5 2% TG + 2% ML 0.7110.09 0.1810.02 Contains 14% PVP rather than 7% PVP.
TC = Transcutanol Example 3 Comparison studies were done on silicone adhesive-17-d-Ngm/EE patches using two types of PVP: a soluble low molecular weight PVP designated PVP-K30 from BASF and an insoluble crosslinked micronized PVP designated PVP-CLM from BASF.
PVP-K30 is dissolved in absolute ethanol. Mixtures of 17-d-Ngm, EE and PVP-K30 were prepared and silicone 4202 and methyl laurate were added thereafter.
The mixture was blended overnight. The mixture was cast on a 3M 1022 liner at a thickness of 15 mil (wet) and dried at 700C for 40 min.
PVP-CLM is available as micronized solids. Silicone 4202 and PVP-CLM were blended together and then methyl laurate, EE, 17-d-Ngm, and ethanol were added. The mixture was blended overnight and cast onto a:3M 1022 liner and dried as above.
Skin flux studies were carried out on the above-described assemblies as in Example 1. The details of these formulations and the results of the skin flux tests are reported in Table 3 below.
Flux (ltglcm2/hr) Formulation 0.1% EE, 1% 17-d-Ngm, ~~% ML, 0.4910.02 0.0510.002 7% PVP-CLM, 86.9°ro silicone 0.1% EE, 1% 17-d-Ngm, i°.~o ML, 0.3710.07 0.0410.008 7% PVP-K30, 86.9% silicone Fxamnle ~
PIB solutions were prepared by dissolving VISTANEX L100, Vistanex L.'~I-MS-LC, and polybutene (INDOPOLT"" H1900) in hexane. Suspensions of PVP-CLM, 17-d-Ngm, EE and various enhancers in ethanol/ethyl acetate were prepared. The PIB
solution was added to the drug suspensions and the resulting mixtures were thoroughly blended. The mixtures were cast as a 10 mil thick (wet) layer onto release liners and dried at 70 ° C for 40 min. SARANEXT'" 2015 backing was laminated to the subassembly. Skin flux studies were carried out on these assemblies as in Example 1. The details of these assemblies and the results of the skin flux studies are reported in Table 4 below.
Y1 'T N N N
I
~ ~ ~ ,~ ~ T
i n ~ s=,' - y: = ~ r -t _ C C ~. . . . " ~ ~. ...~..r. ....
~.
a %
N fV ~r.=; s: 'T - -f , LLZ C ~ . N ~r1 _ ~I ~ ~ = ~~ +; =yr~ I c r,..,N r r. -r '. Y_ N '.-,. '-.=r-r -r T W ~. ~r,: w:
r, V
J
UI J
_ 'n U_ J
U ~ _ _ U_ '~ .
;.!
I r Z a V
~J V :-Z ~ ._ v v ~
U V E'~~ Gi ~
a . z = _ :u . ~ ~ G G
~ ~ ~' L ~r;
._ . _. _'-'_v ~ ..~
L
.r. - .r: C C U
.r - nr,.r, r: -. x r '--.- - X
~~ -i.
_ _ _. ' _ - . ' ~ ~ - , - V
r~7N n r~ ' i V
N
: . , N n. N nJ ~s ~l N
N G
.
~~
C
d C
V
_,' '~
N
~i __ __ _ __ _ __ __ __ __ __ __ __ -t ~ -T -r f~~ -a T N rr N I-.-f N U
T U
~
cc a \_ v, c a _ c;, _ u ,a on ~' u~~ -o f~.N N r: ~" ' N N N N N
r r>
.. .. . . . . ~.
U
G
~p C
W -t -1 T --t 'T -r T -r T T "f,~
. . T ~ (--- . G
r. .r.~r .r .r.~ .r;.r..r..r..r.~
G. _ . r r - . _. _ . _ E
- _ - _ II
_ r~ _ , . _ 3QC~
t1 A composition and nnatrix suitable for hormone rel;: 3cement therapy is prepared as follows. 2% 17~-estradiol, 2% 17-deacetynorgetimate, 20% PVP-CLM and 76%
PIB
adhesive (1:5:2.5:1.5 Vistanex L100:Vistanex LM-MS-LC: Polybutene:ZONESTERT""
85FG) is dissolved in a combination of hexane, ethyl acetate, and ethanol. It was cast onto a polyester release liner and dried at 70°C for 45 minutes. A polyester backing was applied prior to the flux study. The flux study was conducted as described as in Example 1.
Steroid Flux (pg/cmZ/hr) 71-d-N gm 0.10 71-(3-estradio:l 0.20 Transdermal patches having a matrix composed of PIB adhesive, PVP=CLM, lauryl or myristyl lactate, 17-d-Ngm, and EE were made as follows:
The 17-d-Ngm and EE were dissolved in ethyl acetate and the PVP-CL and lauryl lactate or myrist5~l lactate (obtained from ISP VanDYK of Belleville, New Jersey) were added to that solution. A solution of the PIB adhesive (1:5:4 Vistanex L100:Vistanex LM-MS-LC:Indopol I-I190~0) in hexane was added to the steroid solutions with vigorous mixing. N-propanol, at 10'% of the PVP-CLM weight, was added slowly to the final mixtures. The mixtures were cast onto a release liner and dried in an oven at 70°C for 40 minutes. The dried matrix weighed 7.5 mgiem2. The matrix-release liner subassembly was laminated to a polyester (SCOTCHPAKT"" 1012) backing. Another subassembly was laminated to a nonwoven polyester layer (REMAYT"" 2250). The release liner was removed from the backing assembly and it was applied to the nonwoven layer assembly to give a 5 layer composite of: backing/adhesive matrix/nonwoven/adhesive matrix/release liner.
Skin flux studies were carried out on these patches as described in Example 1.
Details of the patches and the results of the flux studies are reported in Table 5 below.
1?
Table 6 Matrix Formulation Skin 17-d-Ngm Flux EE flux Permeabilitypg/cm2/hr pg/cm2/hr 72.85% PIB Low 0.23 0.02 20% PVP-CLM Medium 0.45 0.05 0.1 S% EE High 0.82 0.08 5% lauryl lactate 70.8% PIB Low 0.20 0.03 20% PVP-CLM Medium 0.55 0.08 0.2% EE
2% 71-d-Ngm 7% lauryl lactate 72.8% PIB - 0.64 0.09 20% PVP-CLM
0.2 EE
2% 17-d-Ngm 5% myristyl lactate Modifications of the above-described modes for carrying out the invention that are obvious to those of skill in the field of transdermal patches are intended to be within the scope of the following claims.
17-d-Nam % Enhancer 17_d-Ngm 4 0.5 5% ML + 1% TG 0.65f0.09 0.069+0.007 6 0.5 5% ML + 1 % TG 0.600.04 0.0430.004 6 0.5 14% PGML 0.48f0.04 0.070f0.01 6 0.5 14% (TC:PGML; 0.580.05 0.062f0.01 80:20) 4 0.5 4% TG + 5% ML 0.6410.01 0.07810.01 4 0.5 2% ML 0.5110.08 0.07410.008 2 0.5 2% TG + 2% ML 0.7110.09 0.1810.02 Contains 14% PVP rather than 7% PVP.
TC = Transcutanol Example 3 Comparison studies were done on silicone adhesive-17-d-Ngm/EE patches using two types of PVP: a soluble low molecular weight PVP designated PVP-K30 from BASF and an insoluble crosslinked micronized PVP designated PVP-CLM from BASF.
PVP-K30 is dissolved in absolute ethanol. Mixtures of 17-d-Ngm, EE and PVP-K30 were prepared and silicone 4202 and methyl laurate were added thereafter.
The mixture was blended overnight. The mixture was cast on a 3M 1022 liner at a thickness of 15 mil (wet) and dried at 700C for 40 min.
PVP-CLM is available as micronized solids. Silicone 4202 and PVP-CLM were blended together and then methyl laurate, EE, 17-d-Ngm, and ethanol were added. The mixture was blended overnight and cast onto a:3M 1022 liner and dried as above.
Skin flux studies were carried out on the above-described assemblies as in Example 1. The details of these formulations and the results of the skin flux tests are reported in Table 3 below.
Flux (ltglcm2/hr) Formulation 0.1% EE, 1% 17-d-Ngm, ~~% ML, 0.4910.02 0.0510.002 7% PVP-CLM, 86.9°ro silicone 0.1% EE, 1% 17-d-Ngm, i°.~o ML, 0.3710.07 0.0410.008 7% PVP-K30, 86.9% silicone Fxamnle ~
PIB solutions were prepared by dissolving VISTANEX L100, Vistanex L.'~I-MS-LC, and polybutene (INDOPOLT"" H1900) in hexane. Suspensions of PVP-CLM, 17-d-Ngm, EE and various enhancers in ethanol/ethyl acetate were prepared. The PIB
solution was added to the drug suspensions and the resulting mixtures were thoroughly blended. The mixtures were cast as a 10 mil thick (wet) layer onto release liners and dried at 70 ° C for 40 min. SARANEXT'" 2015 backing was laminated to the subassembly. Skin flux studies were carried out on these assemblies as in Example 1. The details of these assemblies and the results of the skin flux studies are reported in Table 4 below.
Y1 'T N N N
I
~ ~ ~ ,~ ~ T
i n ~ s=,' - y: = ~ r -t _ C C ~. . . . " ~ ~. ...~..r. ....
~.
a %
N fV ~r.=; s: 'T - -f , LLZ C ~ . N ~r1 _ ~I ~ ~ = ~~ +; =yr~ I c r,..,N r r. -r '. Y_ N '.-,. '-.=r-r -r T W ~. ~r,: w:
r, V
J
UI J
_ 'n U_ J
U ~ _ _ U_ '~ .
;.!
I r Z a V
~J V :-Z ~ ._ v v ~
U V E'~~ Gi ~
a . z = _ :u . ~ ~ G G
~ ~ ~' L ~r;
._ . _. _'-'_v ~ ..~
L
.r. - .r: C C U
.r - nr,.r, r: -. x r '--.- - X
~~ -i.
_ _ _. ' _ - . ' ~ ~ - , - V
r~7N n r~ ' i V
N
: . , N n. N nJ ~s ~l N
N G
.
~~
C
d C
V
_,' '~
N
~i __ __ _ __ _ __ __ __ __ __ __ __ -t ~ -T -r f~~ -a T N rr N I-.-f N U
T U
~
cc a \_ v, c a _ c;, _ u ,a on ~' u~~ -o f~.N N r: ~" ' N N N N N
r r>
.. .. . . . . ~.
U
G
~p C
W -t -1 T --t 'T -r T -r T T "f,~
. . T ~ (--- . G
r. .r.~r .r .r.~ .r;.r..r..r..r.~
G. _ . r r - . _. _ . _ E
- _ - _ II
_ r~ _ , . _ 3QC~
t1 A composition and nnatrix suitable for hormone rel;: 3cement therapy is prepared as follows. 2% 17~-estradiol, 2% 17-deacetynorgetimate, 20% PVP-CLM and 76%
PIB
adhesive (1:5:2.5:1.5 Vistanex L100:Vistanex LM-MS-LC: Polybutene:ZONESTERT""
85FG) is dissolved in a combination of hexane, ethyl acetate, and ethanol. It was cast onto a polyester release liner and dried at 70°C for 45 minutes. A polyester backing was applied prior to the flux study. The flux study was conducted as described as in Example 1.
Steroid Flux (pg/cmZ/hr) 71-d-N gm 0.10 71-(3-estradio:l 0.20 Transdermal patches having a matrix composed of PIB adhesive, PVP=CLM, lauryl or myristyl lactate, 17-d-Ngm, and EE were made as follows:
The 17-d-Ngm and EE were dissolved in ethyl acetate and the PVP-CL and lauryl lactate or myrist5~l lactate (obtained from ISP VanDYK of Belleville, New Jersey) were added to that solution. A solution of the PIB adhesive (1:5:4 Vistanex L100:Vistanex LM-MS-LC:Indopol I-I190~0) in hexane was added to the steroid solutions with vigorous mixing. N-propanol, at 10'% of the PVP-CLM weight, was added slowly to the final mixtures. The mixtures were cast onto a release liner and dried in an oven at 70°C for 40 minutes. The dried matrix weighed 7.5 mgiem2. The matrix-release liner subassembly was laminated to a polyester (SCOTCHPAKT"" 1012) backing. Another subassembly was laminated to a nonwoven polyester layer (REMAYT"" 2250). The release liner was removed from the backing assembly and it was applied to the nonwoven layer assembly to give a 5 layer composite of: backing/adhesive matrix/nonwoven/adhesive matrix/release liner.
Skin flux studies were carried out on these patches as described in Example 1.
Details of the patches and the results of the flux studies are reported in Table 5 below.
1?
Table 6 Matrix Formulation Skin 17-d-Ngm Flux EE flux Permeabilitypg/cm2/hr pg/cm2/hr 72.85% PIB Low 0.23 0.02 20% PVP-CLM Medium 0.45 0.05 0.1 S% EE High 0.82 0.08 5% lauryl lactate 70.8% PIB Low 0.20 0.03 20% PVP-CLM Medium 0.55 0.08 0.2% EE
2% 71-d-Ngm 7% lauryl lactate 72.8% PIB - 0.64 0.09 20% PVP-CLM
0.2 EE
2% 17-d-Ngm 5% myristyl lactate Modifications of the above-described modes for carrying out the invention that are obvious to those of skill in the field of transdermal patches are intended to be within the scope of the following claims.
Claims (51)
1. A transdermal patch for preventing ovulation in a woman comprising:
a) a backing layer; and b) a non-acrylate containing matrix layer underlying the backing layer, the matrix layer comprising a mixture of 17-deacetyl norgestimate, lauryl lactate, and a pressure sensitive adhesive comprising at least one of a silicone and polyisobutylene, and being adapted to be in diffusional communication with the skin of the woman and to administer an ovulation-inhibiting amount of 17-deacetyl norgestimate.
a) a backing layer; and b) a non-acrylate containing matrix layer underlying the backing layer, the matrix layer comprising a mixture of 17-deacetyl norgestimate, lauryl lactate, and a pressure sensitive adhesive comprising at least one of a silicone and polyisobutylene, and being adapted to be in diffusional communication with the skin of the woman and to administer an ovulation-inhibiting amount of 17-deacetyl norgestimate.
2. The patch of claim 1 wherein said amount is 150 to 350 µg/day.
3. The patch of claim 1 wherein the pressure sensitive adhesive consists essentially of polyisobutylene and an aliphatic tackifier.
4. A transdermal patch for preventing ovulation in a woman comprising:
a) a backing layer; and b) a non-acrylate containing matrix layer underlying the backing layer, the matrix layer comprising a mixture of 17-deacetyl norgestimate, an estrogen selected from the group consisting of ethinyl estradiol and 17-.beta.-estradiol, lauryl lactate, and a pressure sensitive adhesive consisting essentially of polyisobutylene and an aliphatic tackifier, and being adapted to be in diffusional communication with the skin of a woman and to co-administer an ovulation inhibiting amount of 17-deacetyl norgestimate and estrogen to said woman.
a) a backing layer; and b) a non-acrylate containing matrix layer underlying the backing layer, the matrix layer comprising a mixture of 17-deacetyl norgestimate, an estrogen selected from the group consisting of ethinyl estradiol and 17-.beta.-estradiol, lauryl lactate, and a pressure sensitive adhesive consisting essentially of polyisobutylene and an aliphatic tackifier, and being adapted to be in diffusional communication with the skin of a woman and to co-administer an ovulation inhibiting amount of 17-deacetyl norgestimate and estrogen to said woman.
5. The patch of claim 4 wherein the estradiol is ethinyl estradiol.
6. The patch of claim 5 wherein said amount is 150 to 350 µg/day of 17-deacteyl norgestimate and :from 10 to 35 µg/day of ethinyl estradiol.
7. The patch of claim 4 where the estradiol is 17-.beta.-estradiol.
8. The patch of claim 7 wherein said amount is 150 to 350 µg/day of 17-deacetyl norgestimate and from 30-150 µg/day of 17-.beta.-estradiol.
9. A method of preventing ovulation in a woman comprising affixing to the skin of the woman the transdermal patch of claim 1.
10. The method of claim 9 wherein said amount is 150 to 350 µg/day.
11. A method of preventing ovulation in a woman comprising affixing to the skin of the woman the transdermal patch of claim 7.
12. The method of claim 11 wherein the estrogen is ethinyl estradiol.
13. The method of claim 12, wherein said amount is 150 to 350 µg/day of 17 deacteyl norgestimate and from 10 to 35 µ/day of ethinyl estradiol.
14. A transdermal patch for providing hormone replacement therapy in a woman comprising:
a) a backing layer; and b) a non-acrylate containing matrix layer underlying the backing layer, the matrix layer comprising a mixture of 17-deacetyl norgestimate, an estrogen selected from the group consisting of ethinyl estradiol and 17-.beta.-estradiol, lauryl lactate, and a pressure sensitive adhesive consisting essentially of polyisobutylene and an aliphatic tackifier, and being adapted to be in diffusional communication with the skin of a woman and to co-administer a therapeutic amount of 17-deacetyl norgestimate and estrogen to said skin.
a) a backing layer; and b) a non-acrylate containing matrix layer underlying the backing layer, the matrix layer comprising a mixture of 17-deacetyl norgestimate, an estrogen selected from the group consisting of ethinyl estradiol and 17-.beta.-estradiol, lauryl lactate, and a pressure sensitive adhesive consisting essentially of polyisobutylene and an aliphatic tackifier, and being adapted to be in diffusional communication with the skin of a woman and to co-administer a therapeutic amount of 17-deacetyl norgestimate and estrogen to said skin.
15. The patch of claim 14 wherein the estradiol is ethinyl estradiol.
16. The patch of claim 14 wherein the estradiol is 17-.beta.-estradiol.
17. A use of 17-deacetyl norgestimate in the manufacture of a transdermal patch as defined by claim 14 for hormone replacement therapy.
18. The use of claim 17 wherein the estrogen is ethinyl estradiol.
19. The use of claim 17 wherein said amount of 17 deacetyl norgestimate is about 150 to 350 µg/day and the amount of ethinyl estradiol is from about 10 to 35 µg/day.
20. The patch of claim 3 wherein the tackifier comprises polybutene oil.
21. The patch of claim 3 wherein the matrix layer comprises crosslinked polyvinyl pyrrolidone.
22. The patch of claims 2 or 3 wherein the patch transdermally administers 150 to 350 µg/day of 17-deacetyl norgestimate for 7 consecutive days.
23. The patch of claim 4 wherein the tackifier comprises polybutene oil.
24. The patch of claim 4 wherein the matrix layer comprises crosslinked polyvinyl pyrrolidone.
25. The patch of claim 4 wherein the patch transdermally administers 150 to µg/day of 17-deacetyl norgestimate and a therapeutically effective amount of estrogen for 7 consecutive days.
26. The method of claim 10 wherein the pressure sensitive adhesive consists essentially of polyisobutylene and an aliphatic tackifier.
27. The method of claims 10 or 26 wherein the matrix transdermally administers to 350 µg/day of 17-deacetyl norgestimate for 7 consecutive days.
28. The method of claim 11 wherein the matrix transdermally administers 150 to µg/day of 17-deacetyl norgestimate and a therapeutically effective amount of estrogen for 7 consecutive days.
29. The patch of claim 14 wherein the tackifier comprises polybutene oil.
30. The patch of claim 14 wherein the matrix layer comprises crosslinked polyvinyl pyrrolidone.
31. A transdermal patch comprising:
a backing layer; and a non-acrylate containing; matrix layer underlying the backing layer, the matrix layer comprising a mixture of 17-deacetyl norgestimate, crosslinked polyvinyl pyrrolidone, and a pressure sensitive adhesive consisting essentially of polyisobutylene and an aliphatic resin tackifier, wherein the matrix is adapted to be in diffusional communication with skin to transdermally administer a therapeutically effective amount of 17-deacetyl norgestimate for 7 consecutive days.
a backing layer; and a non-acrylate containing; matrix layer underlying the backing layer, the matrix layer comprising a mixture of 17-deacetyl norgestimate, crosslinked polyvinyl pyrrolidone, and a pressure sensitive adhesive consisting essentially of polyisobutylene and an aliphatic resin tackifier, wherein the matrix is adapted to be in diffusional communication with skin to transdermally administer a therapeutically effective amount of 17-deacetyl norgestimate for 7 consecutive days.
32. The patch of claim 31 wherein the therapeutically effective amount of 17-deacetyl norgestimate prevents ovulation.
33. The patch of claim 31 wherein the matrix administers from 150 to 350 µg/day of 17-deacetyl norgestimate.
34. The patch of claim 31 wherein the tackifier comprises polybutene oil.
35. The patch of claim 31 wherein the matrix further comprises a skin permeation enhancer.
36. The patch of claim 35 wherein the skin permeation enhancer comprises lauryl lactate.
37. The patch of claim 31 wherein the matrix further comprises an estrogen.
38. The patch of claim 37 wherein the estrogen comprises ethinyl estradiol.
39. The use of the transdermal patch of claim 31 to prevent ovulation comprising applying the transdermal patch to the skin of a patient such that the matrix is in diffusional communication with the skin.
40. The use of claim 39 wherein the transdermal administration of 17-deacetyl norgestimate is effective to prevent ovulation.
41. Use of the transdermal patch as defined in claim 31 to prevent ovulation.
42. A use of an ovulation-inhibiting amount of 17-deacetyl norgestimate for preventing ovulation in a woman, wherein the 17-deacetyl norgestimate is administered transdermally to the woman from a matrix comprising a mixture of 17-deacetyl norgestimate and a presure sensitive adhesive comprising at least one of a silicone and polyisobutylene.
43. The use of claim 42 wherein said amount is 175 to 300 µg/day.
44. A use of an ovulation-inhibiting amount of 17-deacetyl norgestimate and an estrogen for preventing ovulation in a woman, wherein the 17-deacetyl norgestimate and the estrogen are co-administered transdermally to the woman from a matrix comprising a mixture of 17-deacetyl norgestimate, an estrogen and a presure sensitive adhesive comprising at least one of a silicone and polyisobutylene.
45. The use of claim 44 wherein the estrogen is ethinyl estradiol.
46. The use of claim 45 wherein said amount is 175 to 300 µg/day of 17-deacetyl norgestimate and from 10 to 35 µg/day of ethinyl estradiol.
47. Use of a 17-deacetyl norgestimate in the manufacture of a transdermal patch for hormone replacement therapy in a woman wherein the 17-deacetyl norgestimate is administered transdermally to the woman from a matrix comprising a mixture of deacetyl norgestimate and a presure sensitive adhesive comprising at least one of a silicone and polyisobutylene.
48. The use of claim 47 wherein the 17-deacetyl norgestimate is about 175 to µg/day.
49. Use of a 17-deacetyl norgestimate and an estrogen in the manufacture of a transdermal patch for hormone replacement therapy in a woman wherein the 17-deacetyl norgestimate and the estrogen are co-administered transdermally to the woman from a matrix comprising a mixture of 17-deacetyl norgestimate, an estrogen and a presure sensitive adhesive comprising at least one of a silicone and polyisobutylene.
50. The use of claim 49 wherein the estrogen is ethinyl estradiol.
51. The use of claim 50 wherein said amount is 175 to 300 µg/day of 17-deacetyl norgestimate and from 10 to 35 µg/day of ethinyl estradiol.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47353195A | 1995-06-07 | 1995-06-07 | |
| US08/473,531 | 1995-06-07 | ||
| US51726395A | 1995-08-21 | 1995-08-21 | |
| US08/517,263 | 1995-08-21 | ||
| PCT/US1996/009396 WO1996040355A1 (en) | 1995-06-07 | 1996-06-06 | Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2222133A1 CA2222133A1 (en) | 1996-12-19 |
| CA2222133C true CA2222133C (en) | 2002-12-24 |
Family
ID=27044166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002222133A Expired - Lifetime CA2222133C (en) | 1995-06-07 | 1996-06-06 | Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US5876746A (en) |
| EP (1) | EP0836506B2 (en) |
| JP (2) | JP3534775B2 (en) |
| KR (1) | KR100301226B1 (en) |
| CN (1) | CN1188189C (en) |
| AT (1) | ATE229828T1 (en) |
| AU (1) | AU703593B2 (en) |
| CA (1) | CA2222133C (en) |
| CZ (1) | CZ292151B6 (en) |
| DE (1) | DE69625483T3 (en) |
| DK (1) | DK0836506T4 (en) |
| ES (1) | ES2190472T5 (en) |
| HU (1) | HU228434B1 (en) |
| IL (1) | IL122432A (en) |
| MX (1) | MX9709666A (en) |
| NO (1) | NO316308B1 (en) |
| NZ (1) | NZ311304A (en) |
| PL (1) | PL181582B1 (en) |
| PT (1) | PT836506E (en) |
| RU (1) | RU2177311C2 (en) |
| UA (1) | UA48973C2 (en) |
| WO (1) | WO1996040355A1 (en) |
Families Citing this family (178)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6407082B1 (en) * | 1996-09-13 | 2002-06-18 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a vitamin D compound |
| DE19549264A1 (en) * | 1995-12-23 | 1997-06-26 | Schering Ag | Contraception procedure and kit |
| US6511970B1 (en) | 1996-09-13 | 2003-01-28 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium |
| US6034074A (en) | 1996-09-13 | 2000-03-07 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a Vitamin D compound |
| US6028064A (en) | 1996-09-13 | 2000-02-22 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of progestin products |
| US6765002B2 (en) | 2000-03-21 | 2004-07-20 | Gustavo Rodriguez | Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium |
| US5939477A (en) * | 1998-02-02 | 1999-08-17 | Dow Corning Corporation | Silicone pressure sensitive adhesive composition containing functionalized polyisobutylene |
| DE19814084B4 (en) * | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's syndrome and process for its preparation |
| DE19834007C1 (en) * | 1998-07-29 | 2000-02-24 | Lohmann Therapie Syst Lts | Estradiol-containing patch for the transdermal application of hormones and its use |
| ES2379471T5 (en) † | 1999-02-08 | 2015-05-26 | Intarcia Therapeutics, Inc | Non-aqueous single phase biocompatible viscous vehicles and procedures for their preparation |
| US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
| US6417227B1 (en) | 1999-04-28 | 2002-07-09 | Cg And Associates | Methods of delivery of cetyl myristoleate |
| WO2001000116A1 (en) * | 1999-06-25 | 2001-01-04 | Schmidt Jonalee M | Hairpiece and method for attaching same |
| DE19943317C1 (en) * | 1999-09-10 | 2001-03-15 | Lohmann Therapie Syst Lts | Plastic films, in particular for use in a dermal or transdermal therapeutic system and process for their manufacture |
| JP4841781B2 (en) * | 1999-11-24 | 2011-12-21 | アジル・セラピューティクス・インコーポレイテッド | Improved transdermal contraceptive delivery system and method |
| US7045145B1 (en) | 1999-11-24 | 2006-05-16 | Agile Therapeutics, Inc. | Transdermal contraceptive delivery system and process |
| US7384650B2 (en) | 1999-11-24 | 2008-06-10 | Agile Therapeutics, Inc. | Skin permeation enhancement composition for transdermal hormone delivery system |
| US6358939B1 (en) | 1999-12-21 | 2002-03-19 | Northern Lights Pharmaceuticals, Llc | Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease |
| US6989377B2 (en) | 1999-12-21 | 2006-01-24 | Wisconsin Alumni Research Foundation | Treating vitamin D responsive diseases |
| US7223418B2 (en) * | 2000-03-07 | 2007-05-29 | Tiejin Limited | Stretchable patch |
| US20010044431A1 (en) * | 2000-03-21 | 2001-11-22 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
| US7235397B1 (en) | 2000-04-14 | 2007-06-26 | Gensys, Inc. | Methods and compositions for culturing spirochete and treating spirochetal diseases |
| USRE44145E1 (en) | 2000-07-07 | 2013-04-09 | A.V. Topchiev Institute Of Petrochemical Synthesis | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
| DE10041478A1 (en) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | New pharmaceutical composition |
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
| US20040039356A1 (en) * | 2000-10-16 | 2004-02-26 | Masayoshi Maki | Compositions for external preparations |
| US20020106402A1 (en) * | 2000-12-05 | 2002-08-08 | Hartwig Rod Lawson | Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use |
| US8840918B2 (en) * | 2001-05-01 | 2014-09-23 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions for tooth whitening |
| US8206738B2 (en) | 2001-05-01 | 2012-06-26 | Corium International, Inc. | Hydrogel compositions with an erodible backing member |
| US20050215727A1 (en) | 2001-05-01 | 2005-09-29 | Corium | Water-absorbent adhesive compositions and associated methods of manufacture and use |
| US8728445B2 (en) | 2001-05-01 | 2014-05-20 | A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Sciences | Hydrogel Compositions |
| US20050113510A1 (en) | 2001-05-01 | 2005-05-26 | Feldstein Mikhail M. | Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components |
| DE60239528D1 (en) * | 2001-05-01 | 2011-05-05 | Corium International Redwood City | TWO-PHASE, WATER-ABSORBING BIOADHESIVE COMPOSITION |
| US8541021B2 (en) | 2001-05-01 | 2013-09-24 | A.V. Topchiev Institute Of Petrochemical Synthesis | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
| US20030026830A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
| US20030027793A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
| WO2003024450A1 (en) * | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating prion diseases |
| WO2003032914A2 (en) * | 2001-10-17 | 2003-04-24 | Eisai Co., Ltd. | Methods for treating substance abuse with cholinesterase inhibitors |
| WO2003063927A2 (en) * | 2001-11-16 | 2003-08-07 | Eisai Co. Ltd | Compositions and methods to treat gastrointestinal disorders |
| WO2003053221A2 (en) * | 2001-12-19 | 2003-07-03 | Eisai Co. Ltd | Methods using proton pump inhibitors |
| CA2478336A1 (en) * | 2002-03-11 | 2003-09-25 | Janssen Pharmaceutica N.V. | Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens |
| JP2005519962A (en) * | 2002-03-11 | 2005-07-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Continuous progestogen contraceptive regimen that inhibits sulfatase |
| JP2005519964A (en) * | 2002-03-11 | 2005-07-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Sulfatase-inhibiting progestogen-only contraceptive regimen |
| US20030219471A1 (en) * | 2002-03-11 | 2003-11-27 | Caubel Patrick Michel | Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens |
| ATE336252T1 (en) * | 2002-03-11 | 2006-09-15 | Janssen Pharmaceutica Nv | CONTINUOUS SULFATASE-INHIBITING PROGESTOGEN CONTAINING HORMONE SUBSTITUTION THERAPY |
| US7223386B2 (en) * | 2002-03-11 | 2007-05-29 | Dow Corning Corporation | Preparations for topical skin use and treatment |
| US20040142914A1 (en) * | 2002-03-11 | 2004-07-22 | Friedman Andrew Joseph | Extended transdermal contraceptive regimens |
| WO2003095623A2 (en) * | 2002-05-10 | 2003-11-20 | The Trustees Of Columbia University In The City Of New York | Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof |
| AU2003298514A1 (en) * | 2002-05-17 | 2004-05-04 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| AU2003241464A1 (en) * | 2002-05-17 | 2003-12-02 | Eisai Co., Ltd. | Compositions and methods using proton pump inhibitors |
| US20070053976A1 (en) * | 2002-05-17 | 2007-03-08 | Eisai R & D Management Co., Ltd. | Novel combination of drugs as antidepressant |
| US20050245492A1 (en) | 2004-04-28 | 2005-11-03 | Lephart Edwin D | Use of equol for treating skin diseases |
| US8668914B2 (en) | 2002-07-24 | 2014-03-11 | Brigham Young University | Use of equol for treating skin diseases |
| DE10234673B4 (en) * | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Hot-melt TTS for the administration of rotigotine and process for its preparation, and use of rotigotine in the manufacture of a hot-melt TTS |
| US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
| US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
| US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
| SI1426049T1 (en) * | 2002-12-02 | 2005-08-31 | Sanol Arznei Schwarz Gmbh | Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease |
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| DE10261696A1 (en) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Device for the transdermal administration of rotigotine base |
| ME00147B (en) | 2003-02-21 | 2010-10-10 | Schering Ag | Uv stable transdermal therapeutic plaster |
| ATE487492T1 (en) * | 2003-02-27 | 2010-11-15 | Eisai R&D Man Co Ltd | PHARMACEUTICAL COMPOSITION FOR TREATING DRUG DEPENDENCE |
| HUP0301981A2 (en) * | 2003-06-30 | 2005-04-28 | Richter Gedeon Vegyészeti Gyár Rt. | Pure d-(17alpha)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3e-and-3z-oxime isomers, process for the synthesis of the mixture of isomers and the pure isomers |
| HUP0301982A2 (en) * | 2003-06-30 | 2005-04-28 | Richter Gedeon Vegyészeti Gyár Rt. | Process for the preparation of high purity d-(17alpha)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-oxime |
| US7816546B2 (en) | 2003-06-30 | 2010-10-19 | Richter Gedeon Vegyeszeti Gyar Rt. | Process for the synthesis of high purity d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-oxime |
| JP2007502831A (en) * | 2003-08-20 | 2007-02-15 | ニトロメッド インコーポレーティッド | Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use |
| AU2004270161A1 (en) * | 2003-08-28 | 2005-03-17 | Nicox S.A. | Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use |
| US20050096311A1 (en) * | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
| JP4965263B2 (en) * | 2003-12-12 | 2012-07-04 | バイエル ファーマ アクチエンゲゼルシャフト | Transdermal delivery of hormones without the need for penetration enhancers |
| US8668925B2 (en) * | 2003-12-12 | 2014-03-11 | Bayer Intellectual Property Gmbh | Transdermal delivery of hormones without the need of penetration enhancers |
| CA2554716A1 (en) * | 2004-01-22 | 2005-08-04 | Nitromed, Inc. | Nitrosated and/or nitrosylated compounds, compositions and methods of use |
| AU2005210637B2 (en) | 2004-01-30 | 2010-09-16 | A.V. Topchiev Institute Of Petrochemical Synthesis | Rapidly dissolving film for delivery of an active agent |
| US20050191338A1 (en) * | 2004-01-30 | 2005-09-01 | Lifeng Kang | Transdermal drug delivery composition comprising a small molecule gel and process for the preparation thereof |
| DE102004028284A1 (en) * | 2004-06-11 | 2006-01-05 | Hexal Ag | Matrix-controlled transdermal therapeutic system based on a hotmelt adhesive for the application of norelgestromin |
| KR20070048229A (en) * | 2004-08-05 | 2007-05-08 | 코리움 인터네셔널, 인크. | Adhesive composition |
| JP4824963B2 (en) * | 2004-08-12 | 2011-11-30 | 日東電工株式会社 | Patch and patch preparation |
| JP4745747B2 (en) * | 2004-08-12 | 2011-08-10 | 日東電工株式会社 | Fentanyl-containing patch preparation |
| US20060121102A1 (en) * | 2004-09-27 | 2006-06-08 | Chia-Ming Chiang | Transdermal systems for the delivery of estrogens and progestins |
| WO2006041855A2 (en) | 2004-10-04 | 2006-04-20 | Nitromed, Inc. | Compositions and methods using apocynin compounds and nitric oxide donors |
| NZ582975A (en) | 2004-10-21 | 2011-07-29 | Durect Corp | Transdermal delivery systems delivering sufentanil |
| US8252319B2 (en) | 2004-10-21 | 2012-08-28 | Durect Corporation | Transdermal delivery system for sufentanil |
| JP2008528507A (en) * | 2005-01-21 | 2008-07-31 | ニトロメッド インコーポレーティッド | Cardiovascular compounds containing heterocyclic nitric oxide donor groups, compositions and methods of use |
| CN1318032C (en) * | 2005-01-24 | 2007-05-30 | 浙江大学 | Ethinyl estradiol gas permeable absorbing paste |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| US20090042819A1 (en) * | 2005-02-16 | 2009-02-12 | Nitromed, Inc. | Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use |
| AU2006218766A1 (en) * | 2005-02-28 | 2006-09-08 | Nicox S.A. | Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use |
| JPWO2006093066A1 (en) * | 2005-02-28 | 2008-08-07 | 久光製薬株式会社 | Adhesive substrate and medical patch preparation containing the adhesive substrate |
| JP2008533031A (en) * | 2005-03-09 | 2008-08-21 | ニトロメッド インコーポレーティッド | Organic nitric oxide enhancing salts, compositions and methods of use of angiotensin II antagonists |
| US20090131480A1 (en) | 2005-04-04 | 2009-05-21 | Eisai Co., Ltd. | Dihydropyridine Compounds for Neurodegenerative Diseases and Dementia |
| US8962013B2 (en) | 2005-05-02 | 2015-02-24 | Bayer Intellectual Property Gmbh | Multi-layered transdermal system with triazine UV absorber |
| US20060253963A1 (en) * | 2005-05-10 | 2006-11-16 | Limbaugh John M | Body keep |
| US20090048219A1 (en) * | 2005-05-23 | 2009-02-19 | Nitromed Inc. | Organic nitric oxide donor salts of nonsteroidal antiinflammatory compounds, compositions and methods of use |
| US7874489B2 (en) * | 2005-06-20 | 2011-01-25 | Authentiform Technologies, Llc | Product authentication |
| US8458475B2 (en) * | 2005-06-20 | 2013-06-04 | Authentiform Technologies, L.L.C. | Systems and methods for product authentication |
| US8247018B2 (en) * | 2005-06-20 | 2012-08-21 | Authentiform Technologies, Llc | Methods for quality control |
| WO2007011763A2 (en) * | 2005-07-15 | 2007-01-25 | 3M Innovative Properties Company | Adhesive sheet and methods of use thereof |
| WO2007016677A2 (en) | 2005-08-02 | 2007-02-08 | Nitromed, Inc. | Nitric oxide enhancing antimicrobial compounds, compositions and methods of use |
| US20070098772A1 (en) * | 2005-09-23 | 2007-05-03 | Westcott Tyler D | Transdermal norelgestromin delivery system |
| EP1945030A4 (en) * | 2005-10-04 | 2009-10-21 | Nitromed Inc | The genetic risk assessment in heart failure: impact of genetic variation of beta 1 adrenergic receptor gly389arg polymorphism |
| AU2006299383A1 (en) * | 2005-10-04 | 2007-04-12 | Nitromed, Inc. | Methods for treating respiratory disorders |
| AU2006299833B2 (en) | 2005-10-12 | 2012-04-12 | Besins Healthcare Luxembourg Sarl | Improved testosterone gel and method of use |
| EP1954685A4 (en) * | 2005-11-16 | 2009-11-11 | Nitromed Inc | Furoxan compounds, compositions and methods of use |
| EP1968584A2 (en) * | 2005-12-20 | 2008-09-17 | Nitromed, Inc. | Nitric oxide enhancing glutamic acid compounds, compositions and methods of use |
| WO2007075542A2 (en) * | 2005-12-22 | 2007-07-05 | Nitromed, Inc. | Nitric oxide enhancing pyruvate compounds, compositions and methods of use |
| EP2010169A4 (en) * | 2006-04-10 | 2010-09-08 | Nitromed Inc | Assessment of heart failure risk using genetic assessment of g-protein beta-3 subunit polymorphism |
| MX2008014870A (en) | 2006-05-30 | 2009-02-12 | Intarcia Therapeutics Inc | Two-piece, internal-channel osmotic delivery system flow modulator. |
| EP3421031A1 (en) | 2006-08-09 | 2019-01-02 | Intarcia Therapeutics, Inc | Osmotic delivery systems and piston assemblies |
| EP2056814B1 (en) | 2006-08-16 | 2014-05-21 | Amderma Pharmaceuticals, Llc | 2,5-dihydroxybenzene compounds for the treatment of psoriasis |
| DE102006050558B4 (en) | 2006-10-26 | 2009-03-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing norelgestromin for contraception and hormone replacement |
| ES2388355T3 (en) | 2006-11-03 | 2012-10-11 | Durect Corporation | Transdemic delivery systems comprising bupivacaine |
| WO2008067409A2 (en) * | 2006-11-28 | 2008-06-05 | Polyplus Battery Company | Protected lithium electrodes for electro-transport drug delivery |
| BRPI0719307A2 (en) * | 2006-12-01 | 2014-02-04 | Nitto Denko Corp | METHOD FOR THE DELETION OF DECOLORATION OVER TIME OF PREPARATION STICKING CONTAINING DONEPEZIL. |
| EP2098232B1 (en) * | 2006-12-01 | 2013-06-05 | Nitto Denko Corporation | Percutaneous absorption preparation |
| US20100099714A1 (en) * | 2007-03-05 | 2010-04-22 | Eisai R&D Management Co., Ltd. | AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases |
| CN101715340A (en) | 2007-04-23 | 2010-05-26 | 精达制药公司 | The mixed suspension preparation of insulinotropic peptide and application thereof |
| JP2010524844A (en) * | 2007-04-26 | 2010-07-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Cinnamide compounds for dementia |
| DE102007020799A1 (en) | 2007-05-03 | 2008-11-06 | Novosis Ag | Transdermal therapeutic system with remifentanil |
| US20090005824A1 (en) * | 2007-06-29 | 2009-01-01 | Polyplus Battery Company | Electrotransport devices, methods and drug electrode assemblies |
| JP5192296B2 (en) * | 2007-07-05 | 2013-05-08 | 日東電工株式会社 | Patches and patch preparations |
| US20100178323A1 (en) | 2007-07-10 | 2010-07-15 | Agis Kydonieus | Dermal Delivery Device |
| US20090069740A1 (en) * | 2007-09-07 | 2009-03-12 | Polyplus Battery Company | Protected donor electrodes for electro-transport drug delivery |
| JP5209433B2 (en) * | 2007-10-19 | 2013-06-12 | 日東電工株式会社 | Patch preparation |
| EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
| CA2725484A1 (en) * | 2008-05-30 | 2009-12-03 | Eisai R&D Management Co., Ltd. | Percutaneously absorbable preparation |
| US20110056863A1 (en) * | 2008-05-30 | 2011-03-10 | Junichi Sekiya | Adhesive preparation containing donepezil, and package of the same |
| WO2010042610A1 (en) | 2008-10-08 | 2010-04-15 | Agile Therapeutics, Inc. | Transdermal delivery |
| WO2010042612A1 (en) | 2008-10-08 | 2010-04-15 | Agile Therapeutics, Inc. | Transdermal delivery |
| ES2734510T3 (en) | 2008-10-08 | 2019-12-10 | Agile Therapeutics Inc | Transdermal administration |
| TWI541246B (en) | 2008-12-08 | 2016-07-11 | 歐陸斯迪公司 | Dihydroetorphine |
| CA2751884C (en) * | 2009-01-14 | 2018-09-25 | Corium International, Inc. | Transdermal administration of tamsulosin |
| EP2410859A4 (en) | 2009-03-27 | 2013-03-13 | Agile Therapeutics Inc | Transdermal delivery |
| SI2462246T1 (en) | 2009-09-28 | 2018-01-31 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
| DE102010026879A1 (en) | 2010-02-11 | 2011-08-11 | AMW GmbH, 83627 | Transdermal system, useful for indicating and preventing multiple sclerosis, immunomodulator including quinolines or isoxazoles, metabolite forming groups, skin protective layer, a reservoir and a carrier impermeable to active substance |
| DE102010026883A1 (en) | 2010-03-11 | 2011-12-15 | Amw Gmbh | Transdermal system useful e.g. for indication of breast cancer with progesterone-receptor positive status, comprises e.g. aromatase inhibitor, active substance puller protection layer, active substance reservoir |
| EP2377540A1 (en) | 2010-03-31 | 2011-10-19 | Hexal AG | Transdermal patch containing 17-deacetyl norgestimate |
| RU2445084C2 (en) * | 2010-04-27 | 2012-03-20 | Государственное образовательное учреждение высшего профессионального образования Смоленская государственная медицинская академия федерального агентства по здравоохранению и социальному развитию | Transdermal plaster |
| DE102011100619A1 (en) | 2010-05-05 | 2012-01-05 | Amw Gmbh | Therapeutic system, useful to treat chronic pain, comprises active agent impermeable carrier, active agent reservoir containing e.g. opioid receptor agonist, optionally active agent-permeable membrane and active agent impermeable layer |
| DE102010026903A1 (en) | 2010-07-12 | 2012-01-12 | Amw Gmbh | Transdermal therapeutic system with avocado oil or palm oil as adjuvant |
| WO2012095548A2 (en) | 2011-01-13 | 2012-07-19 | Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) | Compounds for treating neurodegenerative disorders |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| FR2992325B1 (en) | 2012-06-26 | 2015-05-22 | Ab7 Innovation | MULTIFUNCTIONAL POLYURETHANE MONOPOLYMERIC MULTIFUNCTION SEQUENCE MATRIX AND MANUFACTURING METHOD |
| EP2915098A4 (en) | 2012-10-30 | 2016-07-06 | Certirx Corp | Product, image, or document authentication, verification, and item identification |
| GB201309654D0 (en) | 2013-05-30 | 2013-07-17 | Euro Celtique Sa | Method |
| EP2821071A1 (en) | 2013-07-04 | 2015-01-07 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Compounds for breast cancer treatment |
| WO2015007326A1 (en) | 2013-07-18 | 2015-01-22 | Institut D'investigació Biomèdica De Bellvitge (Idibell) | Agents comprising a terminal alpha-galactosyl moiety for use in prevention and/or treatment of inflammatory diseases |
| KR101881791B1 (en) * | 2013-10-07 | 2018-07-25 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | Methods and compositions for treating withdrawal syndromes using non-sedative dexmedetomidine transdermal compositions |
| TWI629066B (en) | 2013-10-07 | 2018-07-11 | 帝國製藥美國股份有限公司 | Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions |
| KR101948779B1 (en) * | 2013-10-07 | 2019-05-21 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | Dexmedetomidine transdermal delivery devices and methods for using the same |
| EP3054931B1 (en) * | 2013-10-07 | 2020-12-23 | Teikoku Pharma USA, Inc. | Transdermal delivery device for managing pain comprising dexmedetomidine transdermal compositions |
| JP6188933B2 (en) | 2013-10-07 | 2017-08-30 | テイコク ファーマ ユーエスエー インコーポレーテッド | Methods and compositions for transdermal delivery of non-sedating amounts of dexmedetomidine |
| EP2930238A1 (en) | 2014-04-09 | 2015-10-14 | Fundacio Centre de Regulacio Genomica | Compositions for treating cancer |
| EP2949324A1 (en) | 2014-05-27 | 2015-12-02 | Consorci Institut Catala de Ciencies Cardiovasculars | Prevention and/or treatment of ischemia/reperfusion injury |
| EP2957634A1 (en) | 2014-06-20 | 2015-12-23 | Consejo Superior De Investigaciones Científicas | Compounds for prevention and/or treatment of fibrotic diseases |
| EP2977463A1 (en) | 2014-07-25 | 2016-01-27 | Centro de Investigación Biomédica en Red (CIBER) | Methods and agents related to lung diseases |
| EP2987503A1 (en) | 2014-08-22 | 2016-02-24 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Methods and reagents for prevention and/or treatment of infection |
| EP2997977A1 (en) | 2014-09-19 | 2016-03-23 | Fundación de la Comunidad Valenciana Centro de Investigación Principe Felipe | Specific mtor inhibitors in the treatment of x-linked adrenoleukodystrophy |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| EP3067369A1 (en) | 2015-03-11 | 2016-09-14 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Methods and compositions for the treatment of anti-angiogenic resistant cancer |
| EP3085366A1 (en) | 2015-04-22 | 2016-10-26 | Institut du Cerveau et de la Moelle Epiniere-ICM | Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior |
| US20180125860A1 (en) | 2015-05-18 | 2018-05-10 | Agile Therapeutics, Inc. | Contraceptive Compositions and Methods for Improved Efficacy and Modulation of Side Effects |
| KR102650751B1 (en) | 2015-06-03 | 2024-03-22 | 인타르시아 세라퓨틱스 인코포레이티드 | Implant placement and removal systems |
| EP3356384B1 (en) | 2015-09-29 | 2023-11-29 | Paris Sciences et Lettres | Polypeptides comprising vinculin binding sites for the treatment of proliferation and/or adhesion related diseases |
| CN105416940A (en) * | 2015-11-30 | 2016-03-23 | 芜湖成德龙过滤设备有限公司 | Goods shelf convenient to clean |
| EP3219326A1 (en) | 2016-03-14 | 2017-09-20 | Institut Catalá De Ciencies Cardiovasculars (ICCC) | Prevention and/or treatment of ischemia or ischemia/reperfusion injury |
| SG10201913699QA (en) | 2016-05-16 | 2020-03-30 | Intarcia Therapeutics Inc | Glucagon-receptor selective polypeptides and methods of use thereof |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| EP3556359A4 (en) | 2016-12-19 | 2020-08-05 | Nutritape, S.L. | Energising patch for sportspeople |
| AU2018206539A1 (en) | 2017-01-03 | 2019-07-18 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
| WO2018162581A1 (en) | 2017-03-07 | 2018-09-13 | OP2 Drugs | Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ros) production |
| EP3385276A1 (en) | 2017-04-03 | 2018-10-10 | Targedys | Proteins derived from clpb and uses thereof |
| ES2932076T3 (en) | 2017-10-27 | 2023-01-11 | Association Pour La Rech A Ligbmc Ari | Nonsteroidal Selective Glucocorticoid Receptor Agonist Modulators (SEGRAMs) and Uses Thereof |
| EP3569228A1 (en) | 2018-05-17 | 2019-11-20 | Association pour la recherche à l'IGBMC (ARI) | Non-steroidal selective glucocorticoid receptor agonistic modulators (segrams) and uses thereof |
| EP3539975A1 (en) | 2018-03-15 | 2019-09-18 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Micropeptides and uses thereof |
| US20220071330A1 (en) * | 2018-08-07 | 2022-03-10 | Erin Marie Tedesco | Hair Extension Device and Method |
| IL281161B2 (en) | 2018-09-06 | 2024-01-01 | OP2 Drugs | Pharmaceutical composition comprising cyclodextrin compexes of anethole trithione or derivatives thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE655916C (en) * | 1934-03-04 | 1938-01-25 | Mitteldeutsche Stahlwerke Akt | Thrust bearings for lock gates |
| ATE95430T1 (en) * | 1984-12-22 | 1993-10-15 | Sanol Arznei Schwarz Gmbh | ACTIVE PATCHES. |
| CA1272445A (en) * | 1985-02-25 | 1990-08-07 | Yie W. Chien | Transdermal pharmaceutical absorption dosage unit and process of pharmaceutical administration |
| US4818540A (en) * | 1985-02-25 | 1989-04-04 | Rutgers, The State University Of New Jersey | Transdermal fertility control system and process |
| US5296230A (en) * | 1985-02-25 | 1994-03-22 | Rutgers, The State University Of New Jersey | Transdermal fertility control system and process |
| US4883669A (en) * | 1985-02-25 | 1989-11-28 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for estradiol and other estrogenic steroids and process for administration |
| CA1288698C (en) * | 1985-08-30 | 1991-09-10 | Yie W. Chien | Transdermal anti-anginal pharmaceutical dosage |
| US5145682A (en) * | 1986-05-30 | 1992-09-08 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration |
| US5560922A (en) * | 1986-05-30 | 1996-10-01 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process |
| US4906169A (en) * | 1986-12-29 | 1990-03-06 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
| US5023084A (en) * | 1986-12-29 | 1991-06-11 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
| JPH0720866B2 (en) * | 1987-05-15 | 1995-03-08 | 三生製薬株式会社 | Transdermal preparation containing eperisone or tolperisone or their salts |
| US5422119A (en) * | 1987-09-24 | 1995-06-06 | Jencap Research Ltd. | Transdermal hormone replacement therapy |
| US4898920A (en) * | 1987-10-15 | 1990-02-06 | Dow Corning Corporation | Adhesive compositions, controlled release compositions and transdermal delivery device |
| US5656286A (en) † | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US4994267A (en) * | 1988-03-04 | 1991-02-19 | Noven Pharmaceuticals, Inc. | Transdermal acrylic multipolymer drug delivery system |
| US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5788983A (en) * | 1989-04-03 | 1998-08-04 | Rutgers, The State University Of New Jersey | Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes |
| US5232707A (en) * | 1989-07-10 | 1993-08-03 | Syntex (U.S.A.) Inc. | Solvent extraction process |
| US5252334A (en) † | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
| DE3933460A1 (en) * | 1989-10-06 | 1991-04-18 | Lohmann Therapie Syst Lts | OSTROGEN-ACTIVE PLASTER |
| US5508038A (en) * | 1990-04-16 | 1996-04-16 | Alza Corporation | Polyisobutylene adhesives for transdermal devices |
| MY115126A (en) * | 1990-04-27 | 2003-04-30 | Seikisui Chemical Co Ltd | Percutaneously absorbable eperisone or tolperisone preparation. |
| EP0555360A1 (en) * | 1990-10-29 | 1993-08-18 | Alza Corporation | Transdermal contraceptive formulations, methods and devices |
| US5314694A (en) * | 1990-10-29 | 1994-05-24 | Alza Corporation | Transdermal formulations, methods and devices |
| US5232702A (en) * | 1991-07-22 | 1993-08-03 | Dow Corning Corporation | Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices |
| DE4210711A1 (en) † | 1991-10-31 | 1993-05-06 | Schering Ag Berlin Und Bergkamen, 1000 Berlin, De | TRANSDERMAL THERAPEUTIC SYSTEMS WITH CRYSTALIZATION INHIBITORS |
| JP2960832B2 (en) * | 1992-05-08 | 1999-10-12 | ペルマテック テクノロジー アクチェンゲゼルシャフト | Estradiol administration system |
| DE4227989A1 (en) * | 1992-08-21 | 1994-06-09 | Schering Ag | Agent for transdermal application containing 3-keto-desogestrel |
| AU7396294A (en) * | 1993-06-25 | 1995-01-24 | Alza Corporation | Incorporating poly-n-vinyl amide in a transdermal system |
| DE4333595A1 (en) * | 1993-10-01 | 1995-04-06 | Labtec Gmbh | Transdermal therapeutic system for applying drugs to the skin |
| US5741511A (en) * | 1995-04-12 | 1998-04-21 | Sam Yang Co., Ltd. | Transdermal drug delivery device for treating erectile dysfunction |
| WO1996040087A2 (en) * | 1995-06-07 | 1996-12-19 | Cygnus, Inc. | Pressure sensitive acrylate adhesive composition cross-linked with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group |
| US5762956A (en) * | 1996-04-24 | 1998-06-09 | Rutgers, The State University Of New Jersey | Transdermal contraceptive delivery system and process |
| US5783208A (en) * | 1996-07-19 | 1998-07-21 | Theratech, Inc. | Transdermal drug delivery matrix for coadministering estradiol and another steroid |
-
1996
- 1996-06-06 JP JP50172397A patent/JP3534775B2/en not_active Expired - Lifetime
- 1996-06-06 CZ CZ19973932A patent/CZ292151B6/en not_active IP Right Cessation
- 1996-06-06 IL IL12243296A patent/IL122432A/en not_active IP Right Cessation
- 1996-06-06 US US08/660,024 patent/US5876746A/en not_active Expired - Lifetime
- 1996-06-06 CN CNB96195390XA patent/CN1188189C/en not_active Expired - Lifetime
- 1996-06-06 PT PT96921353T patent/PT836506E/en unknown
- 1996-06-06 NZ NZ311304A patent/NZ311304A/en not_active IP Right Cessation
- 1996-06-06 AU AU62597/96A patent/AU703593B2/en not_active Expired
- 1996-06-06 RU RU98100451/14A patent/RU2177311C2/en active
- 1996-06-06 PL PL96323729A patent/PL181582B1/en unknown
- 1996-06-06 AT AT96921353T patent/ATE229828T1/en active
- 1996-06-06 WO PCT/US1996/009396 patent/WO1996040355A1/en active IP Right Grant
- 1996-06-06 EP EP96921353A patent/EP0836506B2/en not_active Expired - Lifetime
- 1996-06-06 DE DE69625483T patent/DE69625483T3/en not_active Expired - Lifetime
- 1996-06-06 HU HU9802326A patent/HU228434B1/en unknown
- 1996-06-06 UA UA98010009A patent/UA48973C2/en unknown
- 1996-06-06 ES ES96921353T patent/ES2190472T5/en not_active Expired - Lifetime
- 1996-06-06 DK DK96921353.7T patent/DK0836506T4/en active
- 1996-06-06 CA CA002222133A patent/CA2222133C/en not_active Expired - Lifetime
- 1996-06-06 KR KR1019970709164A patent/KR100301226B1/en not_active IP Right Cessation
-
1997
- 1997-12-03 NO NO19975586A patent/NO316308B1/en not_active IP Right Cessation
- 1997-12-05 MX MX9709666A patent/MX9709666A/en unknown
-
1998
- 1998-10-02 US US09/165,526 patent/US5972377A/en not_active Expired - Lifetime
-
1999
- 1999-06-28 US US09/340,859 patent/US6071531A/en not_active Expired - Lifetime
-
2003
- 2003-11-05 JP JP2003376231A patent/JP2004043510A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2222133C (en) | Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen | |
| US5693335A (en) | Skin permeation enhancer composition for use with sex steroids | |
| EP0716615B1 (en) | Low flux transdermal potent drug delivery system | |
| US5252334A (en) | Solid matrix system for transdermal drug delivery | |
| US9005653B2 (en) | Transdermal delivery of hormones with low concentration of penetration enhancers | |
| CA2065311C (en) | Solid matrix system for transdermal drug delivery | |
| US20080279915A1 (en) | Matrix-Controlled Transdermal Therapeutic System Based on an Adhesive for Administering Norelgestromin or the Combination Thereof with an Estrogen | |
| US20070098772A1 (en) | Transdermal norelgestromin delivery system | |
| EP2138169B1 (en) | Transdermal delivery system of hormones without penetration enhancers | |
| JPH04342532A (en) | Percutaneous plaster | |
| JPH07101864A (en) | Transdermal absorption plaster | |
| JP3229171B2 (en) | Patch | |
| JPH04342531A (en) | Percutaneous drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20160606 |